全文获取类型
收费全文 | 651篇 |
免费 | 63篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 56篇 |
妇产科学 | 10篇 |
基础医学 | 92篇 |
口腔科学 | 27篇 |
临床医学 | 112篇 |
内科学 | 130篇 |
皮肤病学 | 1篇 |
神经病学 | 63篇 |
特种医学 | 101篇 |
外科学 | 31篇 |
综合类 | 35篇 |
预防医学 | 28篇 |
眼科学 | 1篇 |
药学 | 68篇 |
中国医学 | 2篇 |
肿瘤学 | 20篇 |
出版年
2021年 | 8篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 7篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 14篇 |
2014年 | 7篇 |
2013年 | 15篇 |
2012年 | 15篇 |
2011年 | 28篇 |
2010年 | 10篇 |
2009年 | 21篇 |
2008年 | 17篇 |
2007年 | 55篇 |
2006年 | 29篇 |
2005年 | 15篇 |
2004年 | 17篇 |
2003年 | 15篇 |
2002年 | 25篇 |
2001年 | 23篇 |
2000年 | 18篇 |
1999年 | 14篇 |
1998年 | 29篇 |
1997年 | 28篇 |
1996年 | 27篇 |
1995年 | 21篇 |
1994年 | 21篇 |
1993年 | 11篇 |
1992年 | 13篇 |
1991年 | 8篇 |
1990年 | 20篇 |
1989年 | 18篇 |
1988年 | 21篇 |
1987年 | 17篇 |
1986年 | 18篇 |
1985年 | 20篇 |
1984年 | 12篇 |
1983年 | 11篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 11篇 |
1979年 | 13篇 |
1978年 | 14篇 |
1977年 | 5篇 |
1976年 | 8篇 |
1975年 | 14篇 |
1972年 | 2篇 |
1971年 | 3篇 |
1966年 | 2篇 |
排序方式: 共有780条查询结果,搜索用时 15 毫秒
81.
常咯啉在实验性心律失常狗的药代动力学-药效动力学分析 总被引:1,自引:0,他引:1
用Harris冠脉结扎法诱发的心律失常狗研究常咯啉药代动力学-药效动力学。7只狗按83.33μg·kg-1·min-1静脉滴注60min,在给药期间和停药后不同时间记录ECG及测定血药浓度。C-T数据用药代程序计算药代参数;药效数据用药代-药效同步分析模型计算药效动力学参数,K10, T1/2,Vd,Cl分别为0.0087min-1,78.03min,40.55ml·kg-1和0.421ml·kg-1·min-1;KeO和Ce(50)分别为0.0048min-1和2.01μg·ml-1. 相似文献
82.
83.
84.
小鼠颅神经嵴细胞的培养和特征 总被引:6,自引:4,他引:2
目的:在体外原代培养Balb/c小鼠胚胎的颅神经嵴细胞。为颅面部各种组织细胞的发育研究提供细胞来源。方法:采用胰酶消化法分离小鼠胚胎第8.5天的颅神经管,从小鼠颅神经管中游离出来的细胞即为颅神经嵴细胞,用免疫组织化学方法鉴定细胞的来源,并测定细胞的生长曲线。结果:成功地培养出小鼠的颅神经嵴细胞,其形态类似成纤维样细胞,免疫组化检测结果表明,神经特异性烯醇化酶(NSE)抗体染色结果阳性。细胞的群体倍增时间为43.65h。结论:原代培养的小鼠颅神经嵴细胞生长稳定,来源明确,是颅面部各种细胞的发育和分化研究中一种有用的工具。 相似文献
85.
Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation 总被引:2,自引:0,他引:2
Phillips GL; Wolff SN; Herzig RH; Lazarus HM; Fay JW; Lin HS; Shina DC; Glasgow GP; Griffith RC; Lamb CW 《Blood》1989,73(8):2086-2092
Twenty-six patients with progressive Hodgkin's disease after conventional chemotherapy received intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT); 19 also received additional involved-field radiotherapy. Twenty-one patients [81%, 95% confidence intervals (CI) 61% to 94%] attained complete (n = 18) or partial responses. Ten patients (38%, 95% CI 20% to 59%) are disease- free a median of 4.5 years later (range 3.5 to 7.0 years), including seven patients with continuous complete responses. The likelihood of overall response was not significantly influenced by any clinical or treatment variable examined. However, there was a trend favoring patients with higher Karnofsky scores, and higher scores were associated with attainment of complete responses (P = .06 and P = .02, respectively, Mann-Whitney U test). Both higher Karnofsky scores and shorter durations of disease before transplantation were associated with improved survival in a stepwise Cox multivariate analysis. The chief cause of failure was progression at sites previously involved with Hodgkin's disease. No patient relapsed in the marrow, and two of three patients with a history of marrow involvement with Hodgkin's disease achieved durable complete responses after transplantation. These data suggest that inadequate pretransplant conditioning, and not the reinoculation of occult tumor cells in the autologous marrow, caused most relapses. Fatal treatment-related toxicity occurred in six patients. Three patients died of idiopathic interstitial pneumonitis; each had previously received local mediastinal irradiation before intensive chemoradiotherapy. Intensive chemoradiotherapy and ABMT produces durable responses in some patients with Hodgkin's disease incurable with conventional therapy. Use of such therapies at the first sign of failure with conventional chemotherapy and development of more effective conditioning regimens should further improve results. 相似文献
86.
Wolff SN; Marion J; Stein RS; Flexner JM; Lazarus HM; Spitzer TR; Phillips GL; Herzig RH; Herzig GP 《Blood》1985,65(6):1407-1411
High-dose (HD) cytosine arabinoside (ARA-C) is more effective treatment than conventional-dose ARA-C regimens for patients with relapsed acute nonlymphocytic leukemia (ANLL). We report here that HD ARA-C given during the first remission of ANLL has resulted in long remission durations and a high proportion of patients who survive more than three years free of disease. From August 1979 to September 1983, 36 adult patients with ANLL in first remission received one to three courses of HD ARA-C (3 g/m2 by one-hour infusion every 12 hours for 12 doses on days 1 through 6) alone or with daunorubicin (30 mg/m2 for two or three doses on days 7 through 9). Three patients died of sepsis or hemorrhage during consolidation, and 14 patients have relapsed from five to 48 months after diagnosis. The remaining 19 patients are in continued complete remission (CCR) from 11 to 62 months. Denoting all deaths in remission as relapse, the actuarial probability of CCR is 42% at 62 months, with an apparent plateau in the survival curve. Of the first 22 patients treated, ten remain in CCR from 37 to 62 months with no therapy for at least three years. Due to its heightened anti-leukemic activity, HD ARA-C allows brief but effective consolidation of ANLL in first remission, with long-term disease-free survival comparable to other approaches. 相似文献
87.
Faltynek CR; Princler GL; Rossio JL; Ruscetti FW; Maluish AE; Abrams PG; Foon KA 《Blood》1986,67(4):1077-1082
Patients with hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) were treated with recombinant interferon alpha A (rIFN- alpha A). The binding of iodinated recombinant interferon-alpha to baseline samples of peripheral blood mononuclear cells (PBMCs) from the leukemia patients was compared with clinical responsiveness to rIFN- alpha A. HCL patients (8/10) responded to rIFN-alpha A therapy, whereas none (0/10) of the CLL patients studied responded. The PBMCs from the eight responsive HCL patients bound approximately twice as much iodinated interferon as the PBMCs from nonresponsive CLL patients. This difference was due to more high-affinity receptors per cell with no difference in the affinity of the interferon-receptor interaction. However, because PBMCs from HCL patients were larger than PBMCs from CLL patients, the cell surface receptor density was similar. The leukemic cells from one of the two nonresponsive HCL patients bound iodinated interferon similarly to the cells from the responsive HCL patients, whereas the leukemic cells from the other nonresponsive HCL patient bound considerably less. The rapidity of response of the HCL patients did not correlate with the level of binding of iodinated interferon. Our results suggest that the absolute number of interferon receptors per cell may be only one of several important parameters in the response to rIFN-alpha A therapy, and that the responsiveness of a particular lymphoproliferative disease or a particular patient to rIFN- alpha A therapy cannot be predicted or explained solely by the degree of interaction between IFN and its cell surface receptor. 相似文献
88.
大肠癌免疫组化表达与临床病理的关系 总被引:1,自引:0,他引:1
目的:探讨大肠癌CEA、P53、nm23、Ki-67、MRP免疫组化表达特点和相互关系,及其与临床病理的关系.方法:回顾性分析2003-01/2006-07我院收治的73例大肠癌患者的临床病理及随访资料,并对其石蜡标本采用免疫组化SP染色法检测CEA、P53、nm23、Ki-67、MRP,分析其免疫组化特点及其与临床病理之间的关系.结果:CEA、P53、nm23、Ki-67、MRP在大肠癌中的阳性表达率依次为82.2%、68.5%、75.3%、84.9%和64.4%.CEA、MRP与大肠癌患者的各因素无统计学差异.P53、Ki-67和nm23与肿瘤的Dukes分期和淋巴结转移有关, P53、Ki-67在Dukes C、D期的阳性表达率(依次为82.8%和100%1明显高于Dukes A、B期者(59.1%和75.0%)(P<0.05),而nm23在Dukes C、D期的阳性表达率(58.6%)明显低于Dukes A、B期者(86.4%)(P<0.05).CEA与nm23的表达呈明显的负相关(r=-0.296,P=0.011),而P53和Ki-67表达之间呈现明显的正相关(r= 0.308,P=0.008),其他各指标间的表达无相关性.nm23、P53和Ki-67与预后因素关系明显,nm23在生存期≥3 a患者的阳性表达率(92.9%)高于生存期<3 a者(71.2%)(P<0.05),而P53和Ki-67在生存期≥3 a患者的阳性表达率(依次为42.9%和64.3%)明显低于生存期<3 a者(74.6%和89.8%)(P<0.05).结论:P53、Ki-67和nm23的表达与大肠癌的侵袭转移和预后密切相关.CEA可能是大肠癌的侵袭转移的促进因素.MRP所引起的耐药机制是一个相对独立的机制.CEA、P53、nm23、Ki-67可作为判断大肠癌恶性程度、侵袭转移以及预后的指标. 相似文献
89.
90.
Hiroshi Kurosaka Angelo Iulianella Trevor Williams Paul A. Trainor 《The Journal of clinical investigation》2014,124(4):1660-1671
Cleft lip, which results from impaired facial process growth and fusion, is one of the most common craniofacial birth defects. Many genes are known to be involved in the etiology of this disorder; however, our understanding of cleft lip pathogenesis remains incomplete. In the present study, we uncovered a role for sonic hedgehog (SHH) signaling during lip fusion. Mice carrying compound mutations in hedgehog acyltransferase (Hhat) and patched1 (Ptch1) exhibited perturbations in the SHH gradient during frontonasal development, which led to hypoplastic nasal process outgrowth, epithelial seam persistence, and cleft lip. Further investigation revealed that enhanced SHH signaling restricts canonical WNT signaling in the lambdoidal region by promoting expression of genes encoding WNT inhibitors. Moreover, reduction of canonical WNT signaling perturbed p63/interferon regulatory factor 6 (p63/IRF6) signaling, resulting in increased proliferation and decreased cell death, which was followed by persistence of the epithelial seam and cleft lip. Consistent with our results, mutations in genes that disrupt SHH and WNT signaling have been identified in both mice and humans with cleft lip. Collectively, our data illustrate that altered SHH signaling contributes to the etiology and pathogenesis of cleft lip through antagonistic interactions with other gene regulatory networks, including the canonical WNT and p63/IRF6 signaling pathways. 相似文献